Literature DB >> 8432298

Raised levels of antistreptokinase antibody and neutralization titres from 4 days to 54 months after administration of streptokinase or anistreplase.

H S Lee1, S Cross, R Davidson, T Reid, K Jennings.   

Abstract

Streptokinase and anistreplase are antigenic and their administration often leads to antibody formation. These can cause allergic reactions and/or neutralization of streptokinase with resulting suboptimal treatment. Currently, streptokinase re-administration is considered appropriate for up to 5 days and from 1 year after a previous dose. Antistreptokinase antibody and neutralization titres (NT) were measured in three groups of patients to determine if this practice is appropriate: 1. (early)--36 patients whose titres were measured for at least 5 days after thrombolysis; 2. (late)--57 patients who received thrombolysis 12-54 months previously; 3. (controls)--182 consecutive suspected myocardial infarction patients (without previous exposure to thrombolysis). Results were as follows (mean +/- SEM): 1. (early)--the antibody and/or NT were raised by day 4 in 19.4% of the patients. One patient could have neutralized 1.97 million units (MU) of streptokinase by day 4. (Day 4--antibody 1:39 +/- 11, NT 0.19 +/- 0.05 MU; day 5--1:136 +/- 41 and NT 0.7 +/- 0.43 MU respectively.) 2. (late)--23 patients (40%) had either antibody titres > or = 1:160 and/or NT > 1.5 MU. (12-23 months--antibody 1:243 +/- 43, NT 0.63 +/- 0.15 MU; 24-35 months--1:98 +/- 31 and 0.69 +/- 0.22 MU; 36-54 months--1:87 +/- 14 and 0.54 +/- 0.12 MU.) All titres were significantly higher than the controls (antibody 1:25 +/- 3, NT 0.14 +/- 0.01 MU, P < 0.01). After streptokinase or antistreplase, antibodies are raised from 4 days to at least 54 months. It would seem prudent to avoid their re-administration during this time interval.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8432298     DOI: 10.1093/eurheartj/14.1.84

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  11 in total

1.  BTS guidelines for the management of pleural infection.

Authors:  C W H Davies; F V Gleeson; R J O Davies
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  A rapid agglutination assay to detect anti-streptokinase antibodies.

Authors:  J P McRedmond; N T Mulvihill; M Kane; B Burke; B Aloul; T Forde; M Walsh; D J Fitzgerald
Journal:  Ir J Med Sci       Date:  2004 Oct-Dec       Impact factor: 1.568

3.  Rural Alberta thrombolysis study. Survey of practice patterns for managing acute myocardial infarction.

Authors:  H Hindle; J K Norheim; R Renger
Journal:  Can Fam Physician       Date:  1995-07       Impact factor: 3.275

4.  An Angiographic Study of Intracoronary Streptokinase versus Intravenous Tissue Plasminogen Activator After Failed Coronary Thrombolysis with Intravenous Streptokinase.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 5.  Criteria for drug usage review of thrombolytics in acute myocardial infarction.

Authors:  S McGlynn
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

Review 6.  Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients?

Authors:  J Brügemann; P A de Graeff; J van der Meer; K I Lie
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

7.  Antibodies to streptokinase.

Authors:  K Jennings
Journal:  BMJ       Date:  1996-02-17

8.  Are streptokinase antibodies clinically important?

Authors:  H S Lee; S J Cross; K Jennings
Journal:  Br Heart J       Date:  1993-12

9.  Profiling the immune responses of human patients treated with recombinant streptokinase after myocardial infarct.

Authors:  O Reyes; I Torrens; A G Ojalvo; A Seralena; H E Garay
Journal:  Mol Divers       Date:  2004       Impact factor: 2.943

Review 10.  How safe is the readministration of streptokinase?

Authors:  H S Lee
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.